# Salah-Eddin Al-Batran

Source: https://onco.cc/people/salah-eddin-al-batran/  
OnCo record `salah-eddin-al-batran` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

German oncologist who led FLOT4, the trial that made the FLOT chemotherapy regimen the standard before and after surgery for stomach and oesophago-gastric junction cancer.

## Summary

Salah-Eddin Al-Batran directs the Institute of Clinical Cancer Research at Krankenhaus Nordwest in Frankfurt and led the German AIO group's FLOT4 trial. Its 2019 Lancet report, of which he was first author, showed that perioperative fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) lengthened survival compared with ECF or ECX in resectable gastric or gastro-oesophageal junction adenocarcinoma, replacing the older regimen across Europe.

## Fields

- Kind: Person
- Last checked: 2026-09-18
- Tags: gastric; oesophageal; trialist
- Role: Medical oncologist and trial lead, Krankenhaus Nordwest and Institute of Clinical Cancer Research, Frankfurt
- Specialisms: Gastric and oesophageal cancer; Perioperative chemotherapy; Cooperative-group trials

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [HER2-positive gastric cancer](https://onco.cc/cancers/gastric-her2-positive/), [Oesophageal and junctional adenocarcinoma](https://onco.cc/cancers/oesophageal-adenocarcinoma/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/)
- institutions: [Krankenhaus Nordwest / Institute of Clinical Cancer Research (IKF)](https://onco.cc/institutions/krankenhaus-nordwest/)
- trials: [FLOT4-AIO](https://onco.cc/trials/flot4/)
- key papers: [FLOT4-AIO: perioperative FLOT versus ECF/ECX for resectable gastric or gastro-oesophageal junction adenocarcinoma](https://onco.cc/key-papers/paper-flot4-lancet-2019/)

---
JSON: https://onco.cc/api/v1/entities/salah-eddin-al-batran.json